Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CNP520 50mg
- drug: CNP520 15mg
- other: Matching placebo
Eligibility
Inclusion Criteria:
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.
- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential
- Cognitively unimpaired as evaluated by memory tests performed at screening.
- Participant's willingness to have a study partner.
- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Exclusion Criteria:
- Any disability that could have prevented the participants from completing all study
requirements. -
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within the past 60
months.
- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).
- Contraindication or intolerance to MRI.
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.
- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.
- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.
- Current clinically significant ECG findings.
- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CNP520 50mg
- drug: CNP520 15mg
- other: Matching placebo
Eligibility
Inclusion Criteria:
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.
- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential
- Cognitively unimpaired as evaluated by memory tests performed at screening.
- Participant's willingness to have a study partner.
- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Exclusion Criteria:
- Any disability that could have prevented the participants from completing all study
requirements. -
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within the past 60
months.
- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).
- Contraindication or intolerance to MRI.
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.
- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.
- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.
- Current clinically significant ECG findings.
- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CNP520 50mg
- drug: CNP520 15mg
- other: Matching placebo
Eligibility
Inclusion Criteria:
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.
- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential
- Cognitively unimpaired as evaluated by memory tests performed at screening.
- Participant's willingness to have a study partner.
- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Exclusion Criteria:
- Any disability that could have prevented the participants from completing all study
requirements. -
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within the past 60
months.
- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).
- Contraindication or intolerance to MRI.
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.
- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.
- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.
- Current clinically significant ECG findings.
- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CNP520 50mg
- drug: CNP520 15mg
- other: Matching placebo
Eligibility
Inclusion Criteria:
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.
- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential
- Cognitively unimpaired as evaluated by memory tests performed at screening.
- Participant's willingness to have a study partner.
- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Exclusion Criteria:
- Any disability that could have prevented the participants from completing all study
requirements. -
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within the past 60
months.
- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).
- Contraindication or intolerance to MRI.
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.
- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.
- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.
- Current clinically significant ECG findings.
- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CNP520 50mg
- drug: CNP520 15mg
- other: Matching placebo
Eligibility
Inclusion Criteria:
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.
- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential
- Cognitively unimpaired as evaluated by memory tests performed at screening.
- Participant's willingness to have a study partner.
- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Exclusion Criteria:
- Any disability that could have prevented the participants from completing all study
requirements. -
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within the past 60
months.
- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).
- Contraindication or intolerance to MRI.
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.
- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.
- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.
- Current clinically significant ECG findings.
- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CNP520 50mg
- drug: CNP520 15mg
- other: Matching placebo
Eligibility
Inclusion Criteria:
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.
- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential
- Cognitively unimpaired as evaluated by memory tests performed at screening.
- Participant's willingness to have a study partner.
- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Exclusion Criteria:
- Any disability that could have prevented the participants from completing all study
requirements. -
- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.
- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.
- History of malignancy of any organ system, treated or untreated, within the past 60
months.
- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).
- Contraindication or intolerance to MRI.
- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.
- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.
- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.
- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.
- Current clinically significant ECG findings.
- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.
Ages Eligible for Study
60 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting